Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jo-Ann E Ford

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Pharmacotherapy|February 26, 2008
Iron overload disorders: treatment options for patients refractory to or intolerant of phlebotomyPenny Bring, Nilufar Partovi, Jo-Ann E Ford, et al.
Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie|September 14, 2006
Erythropoietin and hepatitis C therapy: useful adjuvant therapy but remember to treat the patient and not just a numberEric M Yoshida, Anne Dar Santos, Nilufar Partovi, et al.
Canadian Journal of Gastroenterology & Hepatology|May 13, 2015
The Authors respondEric M Yoshida, Victoria Y Kan, Jo-Ann E Ford, et al.
World Journal of Gastroenterology|September 9, 2005
Acute sensorineural hearing loss associated with peginterferon and ribavirin combination therapy during hepatitis C treatment: outcome after resumption of therapyVictor-K Wong, Cindy Cheong-Lee, Jo-Ann-E Ford, et al.
The Annals of Pharmacotherapy|February 15, 2007
Use of hematopoietic growth factors as adjuvant therapy for anemia and neutropenia in the treatment of hepatitis CAnne E Dar Santos, Nilufar Partovi, Jo-Ann E Ford, et al.
Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie|April 17, 2012
Review of boceprevir and telaprevir for the treatment of chronic hepatitis CKyle John Wilby, Nilufar Partovi, Jo-Ann E Ford, et al.
Annals of Hepatology|February 21, 2012
A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patientsKyle J Wilby, Erica D Greanya, Jo-Ann E Ford, et al.
Canadian Journal of Gastroenterology & Hepatology|March 25, 2015
Patient preference and willingness to pay for transient elastography versus liver biopsy: A perspective from British ColumbiaVictoria Yui-Min Kan, Vladimir Marquez Azalgara, Jo-Ann E Ford, et al.
Anticancer Research|July 2, 2014
The effect of doxorubicin loading on response and toxicity with drug-eluting embolization in resectable hepatoma: a dose escalation studyDarren Klass, David Owen, Andrezj Buczkowski, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Pharmacotherapy|February 26, 2008
Iron overload disorders: treatment options for patients refractory to or intolerant of phlebotomyPenny Bring, Nilufar Partovi, Jo-Ann E Ford, et al.
Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie|September 14, 2006
Erythropoietin and hepatitis C therapy: useful adjuvant therapy but remember to treat the patient and not just a numberEric M Yoshida, Anne Dar Santos, Nilufar Partovi, et al.
Canadian Journal of Gastroenterology & Hepatology|May 13, 2015
The Authors respondEric M Yoshida, Victoria Y Kan, Jo-Ann E Ford, et al.
World Journal of Gastroenterology|September 9, 2005
Acute sensorineural hearing loss associated with peginterferon and ribavirin combination therapy during hepatitis C treatment: outcome after resumption of therapyVictor-K Wong, Cindy Cheong-Lee, Jo-Ann-E Ford, et al.
The Annals of Pharmacotherapy|February 15, 2007
Use of hematopoietic growth factors as adjuvant therapy for anemia and neutropenia in the treatment of hepatitis CAnne E Dar Santos, Nilufar Partovi, Jo-Ann E Ford, et al.
Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie|April 17, 2012
Review of boceprevir and telaprevir for the treatment of chronic hepatitis CKyle John Wilby, Nilufar Partovi, Jo-Ann E Ford, et al.
Annals of Hepatology|February 21, 2012
A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patientsKyle J Wilby, Erica D Greanya, Jo-Ann E Ford, et al.
Canadian Journal of Gastroenterology & Hepatology|March 25, 2015
Patient preference and willingness to pay for transient elastography versus liver biopsy: A perspective from British ColumbiaVictoria Yui-Min Kan, Vladimir Marquez Azalgara, Jo-Ann E Ford, et al.
Anticancer Research|July 2, 2014
The effect of doxorubicin loading on response and toxicity with drug-eluting embolization in resectable hepatoma: a dose escalation studyDarren Klass, David Owen, Andrezj Buczkowski, et al.
Pageof 1